Recombinant vector technologies can improve the yield and lower the cost of egg-based influenza vaccine production.
Eluemuno R. Blyden, PhD
Advertisement
Eluemuno R. Blyden, PhD, is the founder and CEO of AfriVax, Inc.
Articles by Eluemuno R. Blyden, PhD
Advertisement
Latest Updated Articles
New Approaches to Improved Vaccine Manufacturing in Embryonated EggsPublished: January 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Ask the Expert: Commenting on Draft Regulations
2
From Parm to Pharm: Avantor, p-Chip Bring COI Compliance to Clinical Consumables
3
SK pharmteco Invests in California Site to Overcome Peptide Purification Bottlenecks
4
A-TEEM: A Novel, Powerful Tool for Evaluating and Monitoring Cell Culture Media
5
